ArticleInternational journal of hematology2025
In vitro evaluation of global coagulation potential of emicizumab and warfarin using rotational thromboelastometry.
Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Augmented emicizumab-driven coagulation potential in hemophilia A state byResearch and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Warfarin inhibits the generation of vitamin K-dependent proteins and emicizumab can prevent bleeding episodes in people with hemophilia A (PwHA), but their combined hemostatic potential remains unclear. We analyzed the coagulation potential of emicizumab combined with warfarin in a simulated model of PwHA. Nineteen samples were collected from ten patients taking warfarin, and the prothrombin time-international normalized ratio (PT-INR) was used to define near-normal (INR 1.2-1.48; n = 4), subtherapeutic (INR 1.56-1.9; n = 7) and therapeutic (INR > 2.0; n = 8) groups. Factor (F)VIII activity (FVIII:C) was neutralized using an anti-FVIII inhibitor antibody (termed FVIII-depleted) before the addition of emicizumab (50 µg/mL). Coagulation potential was measured using Ca2 + -triggered rotational thromboelastometry, and was compared with that in emicizumab-treated PwHA. The average PT-INR in the near-normal, subtherapeutic, and therapeutic groups was 1.3 ± 0.1, 1.7 ± 0.1, and 2.4 ± 0.3, respectively. The hemostatic potential in FVIII-depleted samples mixed with emicizumab in the near-normal group was comparable to that in emicizumab-treated PwHA. The coagulation potential in FVIII-depleted samples after addition of emicizumab in the subtherapeutic and therapeutic groups were lower than that in emicizumab-treated PwHA. PT-INR monitoring could be informative in emicizumab-treated PwHA due to the influence of vitamin K-dependent proteins.
Indexed as
Identifiers
40293607What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.